Last Updated : January 29, 2025
Details
FilesGeneric Name:
teriflunomide
Project Status:
Active
Therapeutic Area:
Multiple Sclerosis (MS)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0752-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Radiologically Isolated Syndrome (RIS)
| Submission received | July 11, 2024 |
|---|---|
| Review initiated | July 12, 2024 |
| Expert committee meeting (initial) | November 21, 2024 |
| Draft recommendation posted for stakeholder feedback | December 12, 2024 |
| End of feedback period | January 03, 2025 |
| Final recommendation posted | - |
| CADTH review report(s) posted | - |
Files
Last Updated : January 29, 2025